Phase 3 Recruiting Network
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastase…
Sponsor: Children's Oncology Group
NCT ID: NCT05235165
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691478
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Network
Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy usi…
Sponsor: Children's Oncology Group
NCT ID: NCT05304585
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Children's National Medical Center — Washington D.C., District of Columbia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer. Stand…
Sponsor: NRG Oncology
NCT ID: NCT05646316
Sites in District of Columbia: - George Washington University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in District of Columbia: - Local Institution - 2106 — Washington D.C., District of Columbia
- Local Institution - 2110 — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…
Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in District of Columbia: - Georgetown University Medical Center — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05985161
Sites in District of Columbia: - Children's National Hospital (Data Collection Only) — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Industry
This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants wi…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT05734066
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting NIH
This phase II trial tests whether atezolizumab in combination with selinexor works to shrink tumors in patients with alveolar soft part sarcoma and whether the study drugs are better than the usual approach in treating this type of cancer.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05333458
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activat…
Sponsor: Carl Allen
NCT ID: NCT04079179
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Phase 1, Phase 2 Recruiting Academic/Other
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will …
Sponsor: St. Jude Children's Research Hospital
NCT ID: NCT04901702
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 2 Recruiting Academic/Other
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The pr…
Sponsor: Nationwide Children's Hospital
NCT ID: NCT05135975
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neu…
Sponsor: Valent Technologies, LLC
NCT ID: NCT04337177
Sites in District of Columbia: - Children's National Research Institute - Children's National Hospital — Washington D.C., District of Columbia
Phase 1 Recruiting Industry
In this Phase I trial for subjects with advanced head \& neck cancer, breast cancer, soft tissue sarcoma or melanoma all subjects will receive open label X-PACT treatment as a intra-tumoral injection. The primary objective will be to estab…
Sponsor: Immunolight, LLC
NCT ID: NCT04389281
Sites in District of Columbia: - Sibley Hospital - Johns Hopkins University — Washington D.C., District of Columbia
Phase 1 Recruiting Academic/Other
This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in particip…
Sponsor: Children's National Research Institute
NCT ID: NCT07172958
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
- Childrens National Hospital — Washington D.C., District of Columbia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in District of Columbia: - MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
Recruiting Network
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may he…
Sponsor: AIDS Malignancy Consortium
NCT ID: NCT05663502
Sites in District of Columbia: - George Washington University — Washington D.C., District of Columbia
Recruiting Industry
This study is a phase IV, pragmatic single-arm prospective, open label study in pediatric (1 years or older) and adult study participants with rare BRAF V600E mutation-positive unresectable or metastatic solid tumors for whom a decision ha…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05868629
Sites in District of Columbia: - Johns Hopkins University — Washington D.C., District of Columbia
Recruiting Academic/Other
The objective of the International Rare Brain Tumor Registry (IRBTR) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed wi…
Sponsor: Children's National Research Institute
NCT ID: NCT05697874
Sites in District of Columbia: - Children's National Hospital — Washington D.C., District of Columbia
Recruiting NIH
Background: \- Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have c…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01109394
Sites in District of Columbia: - Children's National Medical Center — Washington D.C., District of Columbia
Recruiting Academic/Other
The Johns Hopkins Pediatric Radiation Oncology Program is creating a registry that will capture the full 3D radiation dosimetry delivered to its pediatric patients to manage the quality of care provided, as well as to examine the long-term…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT07129317
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study is designed for children, adolescents and young adults undergoing radiation therapy for metastatic sarcoma. The aim of the study is to investigate if the investigators can improve the overall survival of these patients by target…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06796543
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia
NA Recruiting Academic/Other
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the particip…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT05917301
Sites in District of Columbia: - Sibley Memorial Hospital — Washington D.C., District of Columbia